Virbac Stock: Surge of 7.23% Following Annual Forecast Upgrade
The French animal health specialist released its third-quarter 2025 results on Thursday evening, significantly surpassing market expectations. Revenue for the period reached 364.1 million euros, showing a growth of 12.5% at constant exchange rates and scope, where analysts had only expected a 5.5% increase. This performance is largely due to exceptional growth in North America, driven by a restocking effect among certain distributors, as well as the dynamism of pet care ranges in several European regions. Over the first nine months of the year, the group has recorded a revenue of 1.102 billion euros, up organically by 7.8%. With these strong results, Virbac has raised its annual targets and now expects revenue growth of between 5.5% and 7.5% at constant rates and scope, up from a previously forecasted range of 4% to 6%. The adjusted current operating margin remains expected around 16%, despite the temporary impact of a slower than anticipated restart of a production unit.
Stock Performance and Market Reaction
The stock closed Friday's session at 333.50 euros, up 7.23% from the previous day's close of 311 euros. This significant rise occurred in a bearish market context, with the CAC 40 down 0.18% on the same day. Trading volumes remained moderate, with only 0.15% of capital changing hands, a level that reflects a positive yet not overly euphoric investor reaction. Over the past seven days, the stock has accumulated a gain of 4.87%, indicating a recent recovery after a more challenging period. In the medium term, the situation remains mixed as the stock is still down 1.91% over three months and 14.27% over a year, a performance that contrasts sharply with the 9.11% rise of the CAC 40 over the past twelve months. Analysts reacted immediately on Friday morning, with several brokerage houses praising the publication. TP ICAP Midcap raised its price target from 400 to 407 euros, while maintaining its buy recommendation, noting that the group's new targets appear conservative given the outperformance observed since the beginning of the year. Meanwhile, Oddo BHF confirmed its outperformance recommendation and price target of 395 euros, stating that the current momentum constitutes the positive signal awaited by the market. This convergence of favorable opinions contributed to Virbac ranking as the second-best performance of the SBF 120 during the session, just behind EssilorLuxottica.
Technical Analysis and Stock Movement
From a technical standpoint, Friday's session marked a significant breakthrough as the stock closed well above its technical resistance at 326.50 euros. This level, which had been a ceiling for several weeks, was convincingly breached, paving the way for a potential bullish movement towards new targets. The stock is now clearly above its fifty-day moving average, set at 323.34 euros, reflecting a return of buying momentum in the short term. This technical configuration suggests that investors are reassessing the stock positively after a period of wait-and-see marked by a downward drift in recent months. The position of the stock relative to its two-hundred-day moving average, located at 318.42 euros, confirms this favorable reading. The positive gap between the closing price and this long-term average has indeed widened, moving from a near-parity situation to a gap of nearly 15 euros in just a few sessions. This setup indicates that the underlying trend might be reversing after several months of consolidation. Virbac's beta coefficient, measured at -0.09, shows almost no sensitivity to movements in the CAC 40, or even a slight negative decoupling, which can be an asset in an uncertain market environment.
Momentum Indicators and Volatility
Momentum indicators provide additional insight into the current technical situation of the stock. The Relative Strength Index, positioned at 47, is in a neutral zone, neither overbought nor oversold, which leaves room for potential upward movement without imminent reversal signals. This moderate reading suggests that the day's rise has not yet exhausted its bullish potential, although caution remains advisable given the performance already recorded over the week. The MACD, with a signal line at -3.04 and a trend line at -3.28, remains in negative territory, indicating a dynamic that remains fragile in the medium term despite the strong progression recorded on Friday. The Bollinger Bands currently frame the stock's fluctuations between 306.39 euros for the lower bound and 322.96 euros for the upper bound. The close at 333.50 euros means that the price is now above the upper band, a situation that may indicate a resurgence of volatility and an upward extension movement. The Chaikin Money Flow, measured at 0.06, displays a slightly positive value, indicating a moderate but present buying flow, which corroborates the idea of renewed investor interest in the stock. The monthly volatility of 5.67% remains contained, suggesting that the stock is operating in a relatively stable environment compared to other sector values, despite recent movements.
